Skip to main content
PKU HealthCare Corp., Ltd. logo

PKU HealthCare Corp., Ltd. — Investor Relations & Filings

Ticker · 000788 ISIN · CNE0000008M0 LEI · 3003008BFJK1PW2CE998 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,102 across all filing types
Latest filing 2026-05-21 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 000788

About PKU HealthCare Corp., Ltd.

https://www.pku-hc.com

PKU HealthCare Corp., Ltd. specializes in the research, development, manufacturing, and distribution of chemical raw materials and finished medicinal preparations. The company’s portfolio encompasses a wide range of therapeutic categories, including anti-infectives, cardiovascular treatments, endocrine medications, and central nervous system drugs. It manages integrated production facilities capable of large-scale synthesis of Active Pharmaceutical Ingredients (APIs) alongside the formulation of diverse dosage forms. By integrating advanced research capabilities with standardized manufacturing processes, the organization maintains a focus on technological advancement and quality assurance. Its products are supplied to a global network of healthcare providers and industrial clients, supported by various international regulatory certifications for its manufacturing sites.

Recent filings

Filing Released Lang Actions
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a public announcement of the 2025 Annual General Meeting (AGM) resolutions for 北大医药股份有限公司, including detailed voting results for each proposal (attendance, votes for/against/abstain) and legal opinions. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement.
2026-05-21 Chinese
关于持股5%以上股东减持计划时间届满暨减持股份实施情况的公告
Major Shareholding Notification Classification · 96% confidence The document is an announcement by the company regarding a >5% shareholder’s completion of its planned share reduction and details of the shares sold and remaining holdings. This is a notification of changes in a major shareholder’s stake, not a director dealing, share repurchase by the company, or an annual/interim report. It falls under Major Shareholding Notification (MRQ).
2026-05-11 Chinese
关于获得《化学原料药上市申请批准通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the receipt of an official approval notice from a regulatory authority (国家药品监督管理局) for a drug listing application. It describes the drug, its approval, and the potential impact on the company. The document is short (726 characters) and serves as an announcement of a regulatory approval rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-05-07 Chinese
董事会关于独立董事独立性自查情况的专项意见
Board/Management Information Classification · 95% confidence The document is a statement from the company's board regarding the independence of its independent directors, referencing regulatory guidelines and internal company bylaws. It is a specialized opinion on director independence rather than a financial report, management change announcement, or voting result. It does not contain financial data or report publication information. This fits best under Board/Management Information (MANG) as it relates to board member status and governance matters.
2026-04-27 Chinese
2025年年度审计报告
Audit Report / Information Classification · 100% confidence The document contains a detailed audit report including an auditor's opinion, basis for the opinion, key audit matters, and extensive financial statements such as consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes. The presence of an auditor's report with an explicit audit opinion and detailed financial statements indicates this is a full audit report. The document is lengthy (15,000 characters) and contains substantive financial data, not just an announcement or certification. Therefore, it fits the category of an Audit Report / Information (AR). FY 2025
2026-04-27 Chinese
关于公司全资子公司2025年度证券投资情况专项说明
Capital/Financing Update Classification · 95% confidence The document is a detailed explanation regarding the securities investment activities of a wholly-owned subsidiary of the company for the year 2025. It includes investment approval procedures, investment purposes, funding sources, investment scope, detailed investment data, internal control execution, and the impact on the company. The document is not a full annual or interim financial report but a specific disclosure about securities investment activities and related governance. It references regulatory requirements and board approvals but does not contain comprehensive financial statements or earnings highlights. The document is longer than 3,000 characters but less than 5,000 characters, and it is a specific disclosure about investment activities rather than a general regulatory filing or announcement. This fits best with the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including securities investment activities by subsidiaries.
2026-04-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.